Literature DB >> 23396636

Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography().

S Gaiani1, A Avogaro, G C Bombonato, M Bolognesi, F Amor, S Vigili de Kreutzenberg, G Guarneri, D Sacerdoti.   

Abstract

AIM: To evaluate the prevalence, severity, and hemodynamic features of nonalcoholic fatty liver disease (NAFLD) in nonobese diabetics.
METHODS: We studied 100 consecutive nonobese (body mass index [BMI] < 30) patients with type 1 (n = 17) or type 2 (n = 83) diabetes and no known causes of liver disease. Steatosis was diagnosed and graded with ultrasonography. Digital sonographic images of the liver and right kidney were analyzed with dedicated software (HDI-Lab), and the liver/kidney ratio of grey-scale intensity was calculated as an index of the severity of the steatosis. Severity scores ranging from 0 (none) to 5 (severe) were compared with sonographic and Doppler findings (right liver size, portal vein diameter and flow velocity, hepatic and splenic arterial pulsatility indices, hepatic-vein flow profile and A- and S-wave velocities).
RESULTS: The prevalence of steatosis was 24% in type I and 80% in type II diabetes (grade 1 in 17%, grade 2 in 34%, grade 3 in 33%, grade 4 in 9%, grade 5 in 7%). In patients with steatosis (especially those with grades 4-5 disease), hepatic volume was increased (p < 0.005). Portal vein diameter was increased in grade 5 steatosis. The hepatic artery pulsatility index was significantly increased, particularly in grades 4 and 5 (p < 0.0001); portal and A-wave velocities were significantly reduced in grades 3-5 (p < 0.001); and the hepatic vein flow profile was altered in 27% (biphasic: 20%, flat: 7%) patients with steatosis, although there was no correlation with severity.
CONCLUSIONS: NAFLD is very frequent in nonobese diabetics with type 2 but not type 1 disease, and it is associated with hepatomegaly and liver hemodynamic alterations only when it is severe.

Entities:  

Keywords:  Diabetes; Doppler; NAFLD; Sonography; Splanchnic hemodynamics; Steatosis

Year:  2009        PMID: 23396636      PMCID: PMC3553245          DOI: 10.1016/j.jus.2008.12.002

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  21 in total

1.  A physician's hamlet.

Authors:  P Gonnella
Journal:  Ann Intern Med       Date:  1997-10-15       Impact factor: 25.391

2.  Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.

Authors:  F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

3.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

4.  Interobserver and interequipment variability of echo-Doppler examination of the portal vein: effect of a cooperative training program.

Authors:  C Sabbà; C Merkel; M Zoli; G Ferraioli; S Gaiani; D Sacerdoti; L Bolondi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

5.  Liver size evaluated by ultrasound: ROC curves for hepatitis and alcoholism.

Authors:  C Niederau; A Sonnenberg
Journal:  Radiology       Date:  1984-11       Impact factor: 11.105

6.  Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study.

Authors:  D Magalotti; G Marchesini; S Ramilli; A Berzigotti; G Bianchi; M Zoli
Journal:  Dig Liver Dis       Date:  2004-06       Impact factor: 4.088

7.  Interactions of obesity and glucose-stimulated insulin secretion in familial hypertriglyceridemia.

Authors:  Y Maruhama; R Abe; F Okuguchi; S Oikawa; A Ohneda; Y Goto
Journal:  Diabetes       Date:  1978-06       Impact factor: 9.461

8.  Liver cirrhosis: changes of Doppler waveform of hepatic veins.

Authors:  L Bolondi; S Li Bassi; S Gaiani; G Zironi; G Benzi; V Santi; L Barbara
Journal:  Radiology       Date:  1991-02       Impact factor: 11.105

9.  Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus.

Authors:  K R Falchuk; S C Fiske; R C Haggitt; M Federman; C Trey
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

10.  Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound.

Authors:  Alessandro de Moura Almeida; Helma Pinchemel Cotrim; Daniel Batista Valente Barbosa; Luciana Gordilho Matteoni de Athayde; Adimeia Souza Santos; Almir Galvão Vieira Bitencourt; Luiz Antonio Rodrigues de Freitas; Adriano Rios; Erivaldo Alves
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

View more
  9 in total

1.  Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.

Authors:  Claudio Tana; Marco Tana; Stefano Rossi; Mauro Silingardi; Cosima Schiavone
Journal:  J Ultrasound       Date:  2016-03-29

2.  EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice.

Authors:  Jian Cao; Shailendra P Singh; John A McClung; Gregory Joseph; Luca Vanella; Ignazio Barbagallo; Houli Jiang; John R Falck; Michael Arad; Joseph I Shapiro; Nader G Abraham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-02       Impact factor: 4.733

3.  Silymarin in non alcoholic fatty liver disease.

Authors:  Fulvio Cacciapuoti; Anna Scognamiglio; Rossella Palumbo; Raffaele Forte; Federico Cacciapuoti
Journal:  World J Hepatol       Date:  2013-03-27

Review 4.  Hepatic steatosis in type 1 diabetes.

Authors:  Simon E Regnell; Åke Lernmark
Journal:  Rev Diabet Stud       Date:  2012-02-10

5.  Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy.

Authors:  Francesco Francini-Pesenti; Giorgia Querin; Cristina Martini; Sara Mareso; David Sacerdoti
Journal:  Acta Myol       Date:  2018-09-01

6.  Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity.

Authors:  Xinlei Wang; Xiaoqin Zhao; Yunjuan Gu; Xiaohui Zhu; Tong Yin; Zhuqi Tang; Jin Yuan; Wei Chen; Rong OuYang; Lili Yao; Rongping Zhang; Jie Yuan; Ranran Zhou; Yi Sun; Shiwei Cui
Journal:  J Diabetes Res       Date:  2020-05-26       Impact factor: 4.011

Review 7.  Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.

Authors:  Joost Boeckmans; Alessandra Natale; Matthias Rombaut; Karolien Buyl; Vera Rogiers; Joery De Kock; Tamara Vanhaecke; Robim M Rodrigues
Journal:  Cells       Date:  2019-12-21       Impact factor: 6.600

8.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Marieke de Vries; Jan Westerink; Karin H A H Kaasjager; Harold W de Valk
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

9.  Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.

Authors:  Rajalingham Sakthiswary; Grace Yin Lai Chan; Ee Tzun Koh; Khai Pang Leong; Bernard Yu Hor Thong
Journal:  ScientificWorldJournal       Date:  2014-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.